{"a": [["The burden and costs of chronic diseases in low\u2010income and middle\u2010income countries", "2007"], ["Report of the expert committee on the diagnosis and classification of diabetes mellitus", "1999"], ["Standards of medical care in diabetes \u2010 2008", "2008"], ["Standards of medical care in diabetes \u2010 2011", "2011"], ["Type 2 diabetes incidence and socio\u2010economic position: a systematic review and meta\u2010analysis", "2011"], ["Colesevelam HCl: a non\u2010systemic lipid\u2010altering drug", "2003"], ["The relationship of body mass index to diabetes mellitus, hypertension and dyslipidaemia: comparison of data from two national surveys", "2007"], ["Effect of the bile acid sequestrant colesevelam on the pharmacokinetics of pioglitazone, repaglinide, estrogen estradiol, norethindrone, levothyroxine, and glyburide", "2010"], ["GRADEpro. Version 3.2 for Windows", "2008"], ["Epidemiology and costs of diabetes", "2011"], ["Diabetes in Asia: epidemiology, risk factors, and pathophysiology", "2009"], ["Diabetes prevalence and therapeutic target achievement in the United States, 1999 to 2006", "2009"], ["The Farnesoid X receptor: a molecular link between bile acid and lipid and glucose metabolism", "2005"], ["Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo\u2010controlled trial", "2004"], ["The economic burden of diabetes", "2010"], ["Colesevelam hydrochloride (cholestagel): a new, potent bile acid sequestrant associated with a low incidence of gastrointestinal side effects", "1999"], ["Lilly lecture. The triumvirate: beta\u2010cell, muscle, liver. A collusion responsible for NIDDM", "1987"], ["Effects of colesevelam HC1 on sterol and bile acid excretion in patients with type IIa hypercholesterolemia", "2005"], ["Glucose control and vascular complications in veterans with type 2 diabetes", "2009"], ["How important are comprehensive literature searches and the assessment of trial quality in systematic reviews? Empirical study", "2003"], ["Cholestagel, INN\u2010Colesevelam", "2005"], ["Colesevelam lowers glucose and lipid levels in type 2 diabetes: the clinical evidence", "2010"], ["Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes", "2003"], ["Effects of intensive glucose lowering in type 2 diabetes", "2008"], ["Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines", "2004"], ["Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction", "1998"], ["Bile acid salt binding with colesevelam HCl is not affected by suspension in common beverages", "2006"], ["Bile salt sequestration induces hepatic de novo lipogenesis through farnesoid X receptor\u2010 and liver X receptor alpha\u2010controlled metabolic pathways in mice", "2010"], ["Quantifying heterogeneity in a meta\u2010analysis", "2002"], ["Measuring inconsistency in meta\u2010analysis", "2003"], ["Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011", "2011"], ["Endocrine functions of bile acids", "2006"], ["IDF Diabetes Atlas", "2009"], ["Effectiveness of colesevelam hydrochloride in decreasing LDL cholesterol in patients with primary hypercholesterolemia: a 24\u2010week randomized controlled trial", "2001"], ["Clinical utility of bile acid sequestrants in the treatment of dyslipidemia: a scientific review", "2006"], ["Safety considerations with gastrointestinally active lipid\u2010lowering drugs", "2007"], ["Association of diabetes, comorbidities, and A1C with functional disability in older adults: results from the National Health and Nutrition Examination Survey (NHANES), 1999\u20102006", "2010"], ["Reported methodological quality and discrepancies between large and small randomised trials in meta\u2010analyses", "2001"], ["Inadequate treatment of dyslipidemia in people with type 2 diabetes: quality assessment of diabetes care in a Danish County", "2006"], ["Benefits of strict glucose and blood pressure control in type 2 diabetes: lessons from the UK Prospective Diabetes Study", "1999"], ["The case of the misleading funnel plot", "2006"], ["The PRISMA statement for reporting systematic and meta\u2010analyses of studies that evaluate interventions: explanation and elaboration", "1999"], ["Heart disease and stroke statistics \u2010 2010 update: a report from the American Heart Association", "2010"], ["Sulfonylurea induced beta\u2010cell apoptosis in cultured human islets", "2005"], ["Intensive blood pressure control reduces the risk of cardiovascular events in patients with peripheral arterial disease and type 2 diabetes", "2003"], ["Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta\u2010analyses?", "1998"], ["Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report", "2002"], ["National Diabetes Information Clearinghouse (NDIC): National Diabetes Statistics fact sheet, 2011. www.cdc.gov/diabetes/pubs/pdf/ndfs_2011.pdf", "2011"], ["Burden of diabetes in the adult Chinese population: a systematic literature review and future projections", "2010"], ["Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial", "2007"], ["Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes", "2008"], ["Use of the equivalence approach in reproductive health clinical trials", "2001"], ["Clinical Trials. A Practical Approach. 2", "1991"], ["Absorption, distribution and excretion of GT31\u2010104, a novel bile acid sequestrant, in rats and dogs after acute and subchronic administration", "1997"], ["Colesevelam HCl reduces LDL particle number and increases LDL size in hypercholesterolemia", "2006"], ["Regulation of bile acid synthesis by fat\u2010soluble vitamins A and D", "2010"], ["Empirical evidence of bias: dimensions of methodological quality associated with estimates of treatment effects in controlled trials", "1995"], ["Bile acids and metabolic regulation: mechanisms and clinical responses to bile acid sequestration", "2009"], ["Investigating and dealing with publication and other biases", "2001"], ["The socioeconomics of diabetes from a developing country: a population based cost of illness study", "2010"], ["Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38", "1998"], ["Quality of life in type 2 diabetic patients is affected by complications but not by intensive policies to improve blood glucose or blood pressure control (UKPDS 37)", "1999"], ["Definition, diagnosis and classification of diabetes mellitus and its complications. Part I: diagnosis and classification of diabetes mellitus. Provisional report of a WHO consultation", "1998"], ["Prevalence of cardiovascular disease risk factor in the Chinese population: the 2007\u20102008 China National Diabetes and Metabolic Disorders Study", "2012"], ["Global healthcare expenditure on diabetes for 2010 and 2030", "2010"]], "ex": [["Long\u2010term safety and tolerability of colesevelam HCl in subjects with type 2 diabetes", "2010"], ["Colestilan monotherapy significantly improves glycaemic control and LDL cholesterol levels in patients with type 2 diabetes: a randomized double\u2010blind placebo\u2010controlled study", "2010"]], "in": [["Colesevelam hydrochloride therapy in patients with type 2 diabetes mellitus treated with metformin: glucose and lipid effects", "2008"], ["Colesevelam HCl improves glycemic control and reduces LDL cholesterol in patients with inadequately controlled type 2 diabetes on sulfonylurea\u2010based therapy", "2008"], ["Efficacy and safety of colesevelam in patients with type 2 diabetes mellitus and inadequate glycemic control receiving insulin\u2010based therapy", "2008"], ["Initial combination therapy with metformin and colesevelam for achievement of glycemic and lipid goals in early type 2 diabetes", "2010"], ["The effect of colesevelam hydrochloride on insulin sensitivity and secretion in patients with type 2 diabetes: a pilot study", "2010"], ["Colesevelam HCl effects on atherogenic lipoprotein subclasses in subjects with type 2 diabetes", "2009"]]}